Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Marques, IJ (Author) Other; Gomes, I (Author) Other; Pojo, M (Author) Other; Pires, C (Author) Other; Moura, MM (Author) Other; Cabrera, R (Author) Other; Santos, C (Author) Other; van Ijcken, WF (Author) Other; Manuel R Teixeira (Author) ICBAS; Ramalho, JS (Author) Other; Leite, V (Author) Other; Cavaco, BM (Author) Other

Journal

Title: Thyroid

Vol. 31

Pages: 1366-1375

ISSN: 1050-7256

Publisher: Mary Ann Liebert

Indexing

ISI Web of Knowledge - 2 Citations

Scopus - 2 Citations

Other information

Authenticus ID: P-00V-1FK

DOI: 10.1089/thy.2020.0290

Abstract (EN): Background: The molecular basis of familial nonmedullary thyroid cancer (FNMTC) is still poorly understood, representing a limitation for molecular diagnosis and clinical management. In this study, we aimed to identify new susceptibility genes for FNMTC through whole-exome sequencing (WES) analysis of leukocyte DNA of patients from a highly informative FNMTC family. Methods: We selected six affected family members to conduct WES analysis. Bioinformatic analyses were undertaken to filter and select the genetic variants shared by the affected members, which were subsequently validated by Sanger sequencing. To select the most likely pathogenic variants, several studies were performed, including family segregation analysis, in silico impact characterization, and gene expression (messenger RNA and protein) depiction in databases. For the most promising variant identified, we performed in vitro studies to validate its pathogenicity. Results: Several potentially pathogenic variants were identified in different candidate genes. After filtering with appropriate criteria, the variant c.701C>T, p.Thr234Met in the SPRY4 gene was prioritized for in vitro functional characterization. This SPRY4 variant led to an increase in cell viability and colony formation, indicating that it confers a proliferative advantage and potentiates clonogenic capacity. Phosphokinase array and Western blot analyses suggested that the effects of the SPRY4 variant were mediated through the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, which was further supported by a higher responsiveness of thyroid cancer cells with the SPRY4 variant to a MEK inhibitor. Conclusions: WES analysis in one family identified SPRY4 as a likely novel candidate susceptibility gene for FNMTC, allowing a better understanding of the cellular and molecular mechanisms underlying thyroid cancer development.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10